Esperion to Report Second Quarter 2025 Financial Results on August 5
Esperion (NASDAQ: ESPR) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.
Esperion (NASDAQ: ESPR) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 5 agosto 2025, prima dell'apertura del mercato. L'azienda terrà una webcast alle 8:00 a.m. ET per discutere i risultati e fornire aggiornamenti sul business.
Esperion è una società biofarmaceutica commerciale che sviluppa farmaci orali approvati dalla FDA, da assumere una volta al giorno e non appartenenti alla classe delle statine, destinati a pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro farmaci sono supportati dal trial CLEAR Cardiovascular Outcomes con 14.000 pazienti. L'azienda sta inoltre portando avanti un programma di nuova generazione focalizzato sullo sviluppo di inibitori della ATP citrato liasi (ACLYi).
Esperion (NASDAQ: ESPR) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 5 de agosto de 2025, antes de la apertura del mercado. La compañía realizará una transmisión en vivo a las 8:00 a.m. ET para discutir los resultados y proporcionar actualizaciones comerciales.
Esperion es una empresa biofarmacéutica en etapa comercial que desarrolla medicamentos orales aprobados por la FDA, de administración diaria y no estatinas, para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. Sus medicamentos cuentan con el respaldo del ensayo CLEAR Cardiovascular Outcomes con 14,000 pacientes. La empresa también está avanzando en su programa de próxima generación centrado en el desarrollo de inhibidores de la ATP citrato liasa (ACLYi).
Esperion (NASDAQ: ESPR)은 2025년 2분기 재무 실적 발표를 2025년 8월 5일 장 시작 전으로 예정했습니다. 회사는 동부 표준시 오전 8시에 웹캐스트를 개최하여 실적을 논의하고 비즈니스 업데이트를 제공할 예정입니다.
Esperion은 상업 단계의 생명공학 제약 회사로, FDA 승인을 받은 하루 한 번 복용하는 경구용 비스타틴계 심혈관 질환 환자용 약물을 개발하고 있습니다. 이 약물들은 14,000명 환자를 대상으로 한 CLEAR 심혈관 결과 시험으로 뒷받침됩니다. 회사는 또한 ATP 시트르산 분해효소 억제제(ACLYi) 개발에 중점을 둔 차세대 프로그램을 진행 중입니다.
Esperion (NASDAQ : ESPR) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 5 août 2025, avant l'ouverture des marchés. La société organisera un webcast à 8h00 ET pour discuter des résultats et fournir des mises à jour commerciales.
Esperion est une société biopharmaceutique en phase commerciale développant des médicaments oraux, une fois par jour, non-statines, approuvés par la FDA, destinés aux patients atteints de maladies cardiovasculaires avec un LDL-C élevé. Leurs médicaments sont soutenus par l'essai CLEAR Cardiovascular Outcomes de 14 000 patients. La société fait également progresser son programme de nouvelle génération axé sur le développement d'inhibiteurs de l'ATP citrate lyase (ACLYi).
Esperion (NASDAQ: ESPR) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 5. August 2025 vor Börsenbeginn geplant. Das Unternehmen wird um 8:00 Uhr ET ein Webcast veranstalten, um die Ergebnisse zu besprechen und geschäftliche Updates zu geben.
Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das von der FDA zugelassene, orale, einmal täglich einzunehmende Nicht-Statin-Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C entwickelt. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes Studie mit 14.000 Patienten unterstützt. Das Unternehmen arbeitet zudem an einem Next-Generation-Programm zur Entwicklung von ATP-Citrat-Lyase-Inhibitoren (ACLYi).
- None.
- None.
ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When will Esperion (ESPR) report Q2 2025 earnings?
What time is Esperion's Q2 2025 earnings call?
How can I access Esperion's Q2 2025 earnings webcast?
What are Esperion's main products and focus areas?
How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?
